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Abstract
Background: Vitamin E supplements containing tocotrienols are now being recommended for optimum health
but its effects are scarcely known. The objective was to determine the effects of Tocotrienol Rich Fraction (TRF)
supplementation on lipid profile and oxidative status in healthy older individuals at a dose of 160 mg/day for 6
months.
Methods: Sixty-two subjects were recruited from two age groups: 35-49 years (n = 31) and above 50 years (n =
31), and randomly assigned to receive either TRF or placebo capsules for six months. Blood samples were obtained
at 0, 3
rd and 6
th months.
Results: HDL-cholesterol in the TRF-supplemented group was elevated after 6 months (p < 0.01). Protein carbonyl
contents were markedly decreased (p < 0.001), whereas AGE levels were lowered in the > 50 year-old group (p <
0.05). Plasma levels of total vitamin E particularly tocopherols were significantly increased in the TRF-supplemented
group after 3 months (p < 0.01). Plasma total tocotrienols were only increased in the > 50 year-old group after
receiving 6 months of TRF supplementation. Changes in enzyme activities were only observed in the > 50 year-old
group. SOD activity was decreased after 3 (p < 0.05) and 6 (p < 0.05) months of TRF supplementation whereas
CAT activity was decreased after 3 (p < 0.01) and 6 (p < 0.05) months in the placebo group. GPx activity was
increased at 6 months for both treatment and placebo groups (p < 0.05).
Conclusion: The observed improvement of plasma cholesterol, AGE and antioxidant vitamin levels as well as the
reduced protein damage may indicate a restoration of redox balance after TRF supplementation, particularly in
individuals over 50 years of age.
Background
Dietary and supplemental sources of vitamin E isoforms
have been demonstrated to possess unique properties
that can influence critical pathways involved in cancer
[1,2], cardiovascular [3,4] and neurodegenerative disease
[5,6] development. Recent studies have identified toco-
trienol, the lesser known isomer of vitamin E as the
more effective compound in providing such protection
in comparison to the well-established tocopherol [7-14].
The most promising function of tocotrienol has been
reported in neuroprotection [14,15] and stroke preven-
tion with the latter being attributed to the lipid-correc-
tive properties of tocotrienol [11,13]. However, most
data were generated from in vitro studies or by using
animal models. To date, very limited data available from
human intervention study particularly involving supple-
mental vitamin E and its fundamental effects on diseases
and ageing.
Recent interest has focussed on finding compounds
that could intervened the chemical processes underlying
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demonstrated to be also responsible for the ageing phe-
nomena [16,17]. Although vitamin E supplementation
has yielded equivocal results in human intervention stu-
dies largely on a short term basis [18-20], supplementa-
tion studies measuring benefits to cardiovascular end
points are still controversial with some showing no ben-
efits and some even detrimental effects [21-23]. Studies
are warranted to elucidate the underlying mechanism on
the effects of vitamin E in preventing or treating these
diseases that may explain the observed effects.
Most vitamin E supplements available in the market
usually contain only alpha tocopherol. However, recently
with the availability of tocotrienols commercially, the
uses of tocotrienol-containing supplement are more
widespread. There has been a paradigm shift to vitamin
E supplementation where all isomers of vitamin E are
recommended rather than alpha tocopherol alone [24].
However, it has yet to be determined whether supple-
mentation with a mixture of vitamin E isomers contain-
ing high tocotrienol fractions will affect biochemical
parameters and other blood indices and the possible
underlying mechanism. We are interested in investigat-
ing age-associated biochemical changes with tocotrienol
enriched vitamin E supplementation and identifying the
specific oxidation pathways involved.
Different aged individuals respond differently to var-
ious food and vitamin supplementation [25]. Needs for
supplement may be different with the different age
where older people may benefit from supplementation
as they were reported to have lower antioxidant levels
[26].
We previously reported that TRF supplementation
decreased DNA damage in healthy older adults, mostly
in those over 50 years of age, and that the levels of
damage were associated with age [27]. In the present
work, changes in lipoprotein-lipid profile, protein carbo-
nyl content, advanced glycosylation end products
(AGEs), malondialdehyde (MDA) levels, levels of the
antioxidant vitamins E and C, and antioxidant activities
of superoxide dismutase (SOD), catalase (CAT) and glu-
tathione peroxidase (GPx) were measured in a rando-
mized, double-blinded, placebo-controlled intervention
study of TRF supplementation. We also studied the
association between oxidative biomarkers and antioxi-
dant levels to further elucidate the oxidant-antioxidant
balance with increasing age.
Methods
Study design
Healthy volunteers were recruited through screening of
a population study on oxidative stress and ageing.
Selected individuals were aged 35 years and older, non-
smokers, not pregnant, not taking any vitamin
supplements or minerals, alcohol, or drugs, and free of
cardiac, hepatic, renal or any other chronic diseases.
Adult females were recruited as the compliance from
this gender is higher and mostly are non-smokers.
Results of a pre-study consisting a full physical examina-
tion, previous medical history, blood chemistry and hae-
matology were used to confirm suitability. Sixty-two
subjects were recruited from two age groups, 35-49
years (n = 31) and over 50 years (n = 31), and randomly
assigned to receive either Tocotrienol Rich Fraction
(TRF) capsules (160 mg/day) daily in a single evening
dose or an identical placebo for a period of six months.
All subjects were requested to consume the capsules
after dinner to ensure proper absorption [28,29] and
encouraged to maintain their usual lifestyle throughout
the study period. The commercially prepared TRF (Tri
E
® Tocotrienol) is a palm-based vitamin E consisted of
approximately 74% tocotrienols and 26% tocopherol in
soft gelatine capsules containing palm superolein oil,
and was supplied by Sime Darby Bioganic Sdn. Bhd.
(previously known as Golden Hope Bioganic, Selangor,
Malaysia). Each capsules contained approximately 70.4
mg a-tocotrienol, 4.8 mg b-tocotrienol, 57.6 mg g-toco-
trienol, 33.6 mg δ-tocotrienol and 48 mg a-tocopherol.
The capsules given throughout the study were from the
same lot and provided loosely in plastic containers. The
placebo capsules contained only palm superolein oil. In
addition to plasma samples for vitamin E levels, compli-
ance was assessed by capsule counts at each 3-month
interval. The amount of allotted and returned capsules
for each participant is recorded during the interval visits.
The treatment was double blinded throughout the study
period until all data were collected, after which the ran-
domisation code was broken. The protocol of the study
was approved by the Research and Ethics Committee of
the Faculty of Medicine, Universiti Kebangsaan Malay-
sia. Written informed consent was obtained. Subject
demographics are summarised in Table 1.
Sample collection
Blood sampling was performed at baseline (month 0), 3
months and 6 months of supplementation. Venous
blood samples were drawn from fasting subjects into
lithium heparin-coated and K2EDTA-containing tubes
(BD Vacutainer, Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) for plasma extraction while
into a plain tube for serum extraction. Plasma and
serum were immediately separated by centrifugation at
3000 g for 10 minutes. The obtained packed erythro-
cytes were washed three times with 0.9% sodium chlor-
ide solution. Heparinized plasma aliquots were
separated for lipid profiling as well as vitamin C and
vitamin E determination. Plasma-EDTA aliquots were
used for protein carbonyl and MDA quantification
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testing. Washed erythrocytes were used for determina-
tion of antioxidant activities of SOD, CAT and GPx.
Plasma samples for vitamin C determination were
deproteinised with 5% perchloric acid and centrifuged at
1000 g for 2 minutes, and the resulting clear superna-
tant was transferred into new tubes. Lipid profile testing
was done immediately whereas other samples were fro-
zen at -80°C until further analysis.
Lipid profile determination
Plasma cholesterol and triglyceride concentrations were
determined using enzymatic colorimetric kits (Roche
diagnostics GmbH, Indianapolis, USA) on a Hitachi 747
Automatic Analyzer (Boehringer Mannheim, Germany).
High density lipoprotein-cholesterol (HDL-C) was mea-
sured using the precipitation method whereas low den-
sity lipoprotein-cholesterol (LDL-C) was calculated
using Friedewald’s formula.
Plasma vitamin E determination
Plasma tocopherol and tocotrienol were determined by
HPLC. Briefly, stored plasma samples were thawed and
aliquots of 200 µl plasma and 50 µl 95% ethanol
containing 10 µg/ml butylated hydroxytoluene (Sigma
Chemical Co., St. Louis, MO, USA) were pipetted into
tubes, covered and mixed vigorously for 5 seconds. 1 ml
of absolute ethanol (Merck KGaA, Darmstadt, Germany)
was then added to each tube. The tubes were covered
and mixed again before being centrifuged at 1500 g for
15 minutes at 18°C. The bottom pellet was carefully
removed with a spatula. Hexane, 3 ml (Merck KGaA,
Darmstadt, Germany) were then added to each tube and
mixed vigorously for 5 minutes. The samples were then
centrifuged at 1500 g for 15 minutes at 18°C. After cen-
trifugation, a portion of the upper layer (2.5 ml) was
carefully removed, placed in new tubes and vacuum-eva-
porated for 40 minutes. The dried sample residue was
then reconstituted in 100 µl HPLC grade hexane (Merck
KGaA, Darmstadt, Germany), vortexed, and passed
through a 0.45 µm filter to remove any non-dissolved
particles. The samples were then transferred to amber
vial inserts with care taken to avoid air bubbles and ana-
lysed by HPLC using a Shimadzu RF-10A XL fluores-
cence detector (Shimadzu Corporation, Kyoto, Japan) at
an excitation wavelength of 294 nm and an emission
wavelength of 330 nm. Isomers a-tocopherol, g-toco-
pherol, a-tocotrienol, g-tocotrienol and δ-tocotrienol
Table 1 Baseline and intervention characteristics of the study groups
Placebo (n = 30) TRF (n = 32)
35-49 years > 50 years 35-49 years > 50 years
Age (years) 44.7 ± 0.9
a 59.1 ± 1.7
a 44.5 ± 1.0
b 56.1 ± 1.2
b
Blood pressure (mmHg)
Systolic
Baseline (0 month) 121 ± 2.8
c 137 ± 3.6
c 121 ± 3.5
d 131 ± 3.3
d
3 months 123 ± 2.4
f 137 ± 5.1
f 121 ± 3.4 131 ± 3.5
6 months 120 ± 2.5
g 135 ± 5.0
g 122 ± 3.6 132 ± 3.3
Diastolic
Baseline (0 month) 75.4 ± 1.9
e 82.0 ± 2.7
e 80.6 ± 2.8 81.3 ± 2.6
3 months 73.7 ± 1.7 79.2 ± 2.9 79.2 ± 2.6 82.3 ± 2.6
6 months 75.7 ± 2.8 79.2 ± 3.3 79.0 ± 3.1 82.8 ± 1.9
Pulse (beat/minute)
Baseline (0 month) 73 ± 2 73 ± 3 70 ± 3 70 ± 2
3 months 70 ± 2 72 ± 2 71 ± 3 71 ± 2
6 months 71 ± 2 71 ± 3 69 ± 3 72 ± 2
Body mass index (kg/m
2)
Baseline (0 month) 27.5 ± 1.2 26.3 ± 0.6 26.3 ± 0.7 27.7 ± 1.3
3 months 27.5 ± 1.2 25.0 ± 1.0 25.6 ± 0.6 27.4 ± 1.2
6 months 26.8 ± 1.2 25.2 ± 1.0 25.7 ± 0.7 27.1 ± 1.1
Fasting blood glucose (mmol/L)
Baseline (0 month) 5.53 ± 0.33 5.34 ± 0.13 5.74 ± 0.30 5.49 ± 0.10
3 months 5.40 ± 0.44 5.37 ± 0.10 5.59 ± 0.22 5.24 ± 0.15
6 months 5.55 ± 0.49 5.28 ± 0.14 5.42 ± 0.19 5.47 ± 0.11
Values are expressed as mean ± SEM.
Same letters indicate significant difference between 35-49 and > 50 year-old groups.
a: p < 0.001, b: p < 0.001, c: p < 0.001, d: p < 0.05, e: p < 0.05, f: p < 0.001, g: p < 0.01
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Silica column (Alltech Associated, Inc, IL, USA) and
eluted with a mobile phase of 99:1 (v/v) hexane-isopro-
panol at a flow rate of 1.5 ml per minute. The identity
of each compound was confirmed by co-elution with
spiked standard. All external standards used were
obtained from Malaysian Palm Oil Board (MPOB),
Malaysia. The peaks were quantified and integrated with
Shimadzu Class-VP™ version 6.1 LC Workstation soft-
ware (Shimadzu Corporation, Kyoto, Japan).
Plasma vitamin C determination
The measurement of plasma vitamin C (ascorbic acid)
was performed using HPLC as described by Pachla and
Kissinger [30]. Plasma ascorbic acid was chromatogra-
phically separated on a 25 cm VYDAC
® Genesis C-18 4
µm column (Grace Davison, USA) using a mobile phase
containing 0.04 M sodium acetate, 0.48 mM disodium
EDTA, 2.9 mM tetrabutylammonium hydroxide and
1.4% methanol at pH 4.75. Detection was performed on
an electrochemical detector (Gilson model 142, Gilson
Medical Electronics S.A., Villiers-le-Bel, France) set at
an applied potential of +700 mV and referenced to an
Ag/AgCl electrode, with a flow rate of 1 ml/min and
sensitivity of 100 nA/V on a Gilson HPLC set (Gilson
Medical Electronics S.A., Villiers-le-Bel, France). Assay
calibration was performed for each run using six con-
centrations of the calibrator (0, 2, 4, 6, 8, 10 and 12 mg/
L). Stored deproteinised plasma samples were thawed,
added with 5 mg/L 3,4-dihydroxybenzylamine (Sigma
Chemical Co., USA) and spiked with 5 mg/L ascorbic
acid (Sigma Chemical Co., St. Louis, MO, USA). 3,4-
dihydroxybenzylamine was added to all samples and
calibrators as an internal standard whereas uric acid Rai-
chem™ (Reagents Applications Inc., USA) was injected
separately for peak identification. All samples were fil-
tered through a 0.45 µm membrane before being sub-
jected to HPLC and all peaks were baseline separated.
Ascorbic acid, 3,4-dihydroxybenzylamine and uric acid
peaks were resolved and detected within 11 minutes of
run time and were identified using the retention times
of calibrators. Peaks were integrated using peak-area
ratios of ascorbic acid to 3,4-dihydroxybenzylamine.
Plasma protein carbonyl determination
Carbonyl content in oxidatively-modified proteins was
assayed using the Cayman Chemical protein carbonyl
assay kit (Cayman Chemical Company, Ann Arbor, MI,
USA) based on the method of Levine et al. [31] by fol-
lowing the manufacturer instructions. Briefly, 2,4-dini-
trophenyl-hydrazine (DNPH) reacts with protein
carbonyls, forming a Schiff base to produce the corre-
sponding hydrazone. The protein-hydrazone produced
was quantified at an absorbance of 370 nm with an
extinction coefficient of 22,000 M
-1cm
-1.E a c hs a m p l e
was assayed with a parallel control and the concentra-
tion of carbonyls was determined after correction with
the respective control. The carbonyl content was then
standardized against the protein concentration in the
sample and expressed as nmol carbonyl per mg protein.
The amount of protein was calculated from a bovine
serum albumin (Sigma Chemical Co., St. Louis, USA)
standard curve (0.25-2.0 mg/ml) read at 280 nm.
Serum AGE determination
Serum advanced glycosylation end products (AGEs) was
measured with an in-house competitive enzyme immu-
noassay technique developed by Wan Nazaimoon and
Khalid [32]. Briefly, microtitre wells were coated with
AGE-BSA at 8 µg/ml followed by an overnight incuba-
tion with 20 µl of the prediluted sample (1:6) and 80 µl
anti-AGE-KLH (1:8000). HRP-labelled goat anti-rabbit
(1:3000) was used as the secondary antibody and
3,5’,5,5’-tetramethylbenzidine dihydrochloride (Sigma
Chemical Co., St. Louis, USA) as the substrate. The col-
our reaction was stopped with 1.25 M sulphuric acid
and the absorbance was read at 450 nm with reference
at 620 nm. All samples were assayed in triplicate and
assay performance was monitored using a set of in-
house quality control sera containing three different
levels of AGE.
Plasma MDA determination
Plasma malondialdehyde (MDA) was determined by
HPLC based on the derivatisation of MDA with 2,4-
dinitrophenylhydrazine (DNPH) (Sigma-Aldrich, St.
Louis, MO, USA) as described by Pilz et al. [33] with
some modifications. Briefly, stored plasma samples were
thawed and aliquots of 250 µl plasma were mixed with
50 µl 6 M sodium hydroxide (Merck, Germany). The
sample mixture was incubated at 60°C for 30 minutes in
a water bath. After cooling to room temperature, the
hydrolysed sample was then acidified with 125 µl 35%
(v/v) perchloric acid to precipitate proteins and centri-
fuged at 6000 g for 10 minutes at 18°C. The supernatant
was transferred into fresh tubes and the sample was
then derivatised with 50 µl 5 mM DNPH for 30 minutes
at room temperature. Derivatised samples were used for
HPLC analysis and protected from light from this step
onwards.
Analytical HPLC separations were performed on a
Shimadzu Chromatographic system (Shimadzu Class-
VP™ version 6.1 LC Workstation software, Shimadzu
Corporation, Kyoto, Japan) with a diode array detector
equipped with an auto injector and operated at 310 nm
on a 150 mm × 3.9 mm, 5 µm alphaBond C18 column
(Alltech Associated, Inc. IL, USA). Samples and stan-
dards were eluted with a mobile phase consisting of 380
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with 0.2% (v/v) acetic acid and degassed at a flow rate
of 0.6 ml/min. The plasma MDA level was calculated
from a calibration curve prepared by acidic hydrolysis of
1,1,3,3-Tetraethoxypropane (TEP) (Sigma-Aldrich, St.
Louis, MO, USA).
Determination of erythrocyte antioxidant enzymes
SOD, CAT and GPx activities in the hemolysates were
expressed as U/mg Hb. Erythrocyte Cu, Zn-SOD activity
was assayed using the spectrophotometric indirect inhi-
bition technique of Beyer and Fridovich, which is based
on the ability of SOD to inhibit the photoreduction of
nitro blue tetrazolium [34]. CAT activity was measured
in erythrocytes using the method of Aebi [35] with
hydrogen peroxide as the substrate. This method is
based on the decomposition of hydrogen peroxide and
measured by decreased absorbance at 240 nm. GPx
activity was measured in erythrocytes using the coupled
method of Paglia and Valentine with t-butyl hydroper-
oxide as the substrate [36]. Hemoglobin was assayed
using the cyanmethemoglobin procedure (Eagle Diag-
nostics, Desoto, Texas, USA) based on the determina-
tion of cyanmethemoglobin at 540 nm.
Statistical Analysis
Statistical analysis was performed using Statistical Pack-
age for Social Sciences (SPSS) Version 11.5 (Chicago,
Illinois, USA). Mixed model analysis of variance
(ANOVA) was used to compare changes from baseline
to 3 and 6 months for all variables to ascertain the
effects of treatment. One way analysis of variance was
used to identify significant differences between age
groups. The associations of all parameters were assessed
by partial correlations and analyses of covariance to
account for the increased proportion of women in the
study group. Pearson’s correlation coefficient was deter-
mined for baseline variables to determine their relation-
ships. Mauchly’s test of sphericity was used to assess the
homogeneity of variance and Dunnett’s test was per-
formed to compare the means of the treatment group to
the means of the control group. Bonferroni’s adjustment
was applied to control the inflation of Type 1 error
across multiple tests. All data are presented as mean +
standard error of the mean (SEM). The null hypothesis
was tested using a 2-tailed a < 0.05 criterion. PS Pro-
gram version 2.1.31 was used to determine the power of
study in which the probability of rejecting the null
hypothesis with Type I error was set at a =0 . 0 5 ,g i v e n
the specified sample size n = 30, a standard deviation s
= 0.104 and when the true difference in population
means was δ = 0.097. The statistical power obtained
from our approach was 0.9977.
Results
Subject characteristics
The baseline characteristics of subject age, gender, blood
pressure, pulse, body mass index and fasting blood glu-
cose in the TRF groups were similar to those in the pla-
cebo groups (Table 1). Systolic and diastolic blood
pressure in the younger group (35-49 years old) were
significantly lower than those in the older group (over
50 years old) while no significant differences was
observed between groups regarding to pulse, body mass
index (BMI) or fasting blood sugar (FBS). None of these
clinical parameters showed statistical difference upon
supplementation except for BMI (Table 1) where the
younger group who received TRF demonstrated reduc-
tions in BMI at 3 months (p = 0.024) and 6 months (p
< 0.001).
Lipid profile
Plasma total cholesterol was within the normal range in
all subjects before supplementation. There was no sig-
nificant difference in lipids level between the younger
and older groups at baseline (Table 2). A statistically
significant effect for duration of treatment was observed
in HDL-C in TRF group (F = 4.196, p = 0.020, effect
size = 0.139, power = 0.713). The HDL-C level in the
younger group increased significantly after 6 months of
Tocotrienol supplementation (p = 0.014) as compared
to the baseline, while in the > 50 year-old group, a non-
significant elevation of 8% was observed. However, the
plasma ratio of HDL-C to total cholesterol improved in
both younger (p = 0.007) and older groups (p = 0.029)
with supplementation. Values obtained for all lipid vari-
ables were within the normal range.
Antioxidant vitamins
Plasma vitamin E levels were corrected for cholesterol
levels. Increased plasma total vitamin E concentrations
were evident after 3 months in the treatment group (F =
9.491, p = 0.006, effect size = 0.311, power = 0.836) but
not in placebo group (Table 3). Further grouping of sub-
jects by age (Table 4) revealed significant increases in
lipid-corrected total vitamin E in both 35-49 year-old
and > 50 year-old groups after 6 months (F = 10.233, p
= 0.011, effect size = 0.532, power = 0.812 and F =
43.707, p < 0.001, effect size = 0.785, power = 1 respec-
tively), but in the > 50 year-old group, levels had signifi-
cantly increased as early as 3 months after starting
treatment (F = 6.933, p = 0.022, effect size = 0.366,
power = 0.677).
Similar results were observed for plasma tocopherol
concentration. Changes in plasma level of tocopherol
were statistically significant with duration of treatment
(F = 12.896, p < 0.001, effect size = 0.380, power =
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lipid-corrected total tocopherol levels after 3 and 6
months in the > 50 year-old group (F = 8.043, p =
0.015, effect size = 0.401, power = 0.740 and F = 47.069,
p < 0.000, effect size = 0.797, power = 1 respectively) as
compared to the younger age group. The 35-49 year-old
group only showed increased levels of lipid-corrected
tocopherols after 6 months of supplementation (F =
9.445, p = 0.013, effect size = 0.512, power = 0.781).
Overall, lipid-corrected tocotrienol levels were signifi-
cantly increased in TRF supplemented subjects when
compared to baseline and placebo-receiving subjects
after 6 months (F = 10.068, p = 0.005, effect size =
0.324, power = 0.857). However, further increases in
tocotrienol levels were only observed in the > 50 year-
old group after 6 months of treatment (F = 11.197, p =
0.006, effect size = 0.483, power = 0.866). Regardless of
the treatment type, levels of lipid-corrected total toco-
trienols in the older group were lower than in the
younger group. With treatment, however, levels of lipid-
corrected total tocotrienols in older subjects approached
levels observed in younger subjects.
Table 2 Lipid profiles of study groups
Age group
35-49 years > 50 years
Placebo TRF Placebo TRF
TC (mmol/L)
Baseline (0 month) 5.12 ± 0.19 5.34 ± 0.18 5.30 ± 0.20 5.43 ± 0.19
3 months 4.91 ± 0.17 5.39 ± 0.16 5.39 ± 0.18 5.43 ± 0.20
6 months 5.04 ± 0.17 5.47 ± 0.15 5.34 ± 0.21 5.44 ± 0.20
HDL-C (mmol/L)
Baseline (0 month) 1.37 ± 0.07 1.24 ± 0.07 1.35 ± 0.09 1.36 ± 0.10
3 months 1.42 ± 0.10 1.32 ± 0.06 1.47 ± 0.07 1.32 ± 0.10
6 months 1.41 ± 0.10 1.42 ± 0.07* 1.28 ± 0.07
a 1.47 ± 0.07
a
LDL-C (mmol/L)
Baseline (0 month) 3.28 ± 0.18 3.40 ± 0.20 3.28 ± 0.20 3.42 ± 0.15
3 months 2.99 ± 0.17 3.45 ± 0.15 3.18 ± 0.17 3.45 ± 0.18
6 months 3.15 ± 0.17 3.40 ± 0.15 3.53 ± 0.16 3.23 ± 0.18
Triglycerides (mmol/L)
Baseline (0 month) 1.12 ± 0.15 1.39 ± 0.20 1.41 ± 0.19 1.46 ± 0.26
3 months 1.23 ± 0.12 1.25 ± 0.17 1.58 ± 0.23 1.44 ± 0.25
6 months 1.02 ± 0.10
b 1.48 ± 0.25 1.45 ± 0.25
b 1.57 ± 0.30
HDL-C/TC
Baseline (0 month) 26.58 ± 1.44 23.14 ± 1.63 26.30 ± 2.26 24.73 ± 1.56
3 months 28.53 ± 1.97 24.82 ± 1.36 27.30 ± 2.21 24.53 ± 1.81
6 months 28.89 ± 1.67 25.91 ± 1.53** 24.92 ± 1.82
c 28.13 ± 1.52*
c
Values are expressed as mean ± SEM
Abbreviations: TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol
Symbols indicate significant difference from baseline (0 month)
*: p < 0.05, **: p < 0.01
Same characters indicate significant difference as compared to placebo group.
a: p = 0.022, b: p = 0.022, c: p = 0.04
Table 3 Plasma antioxidant vitamins in placebo and TRF groups
Duration
Antioxidant vitamins 0 month 3 months 6 months
Placebo TRF Placebo TRF Placebo TRF
Lipid-corrected total vitamin E (g/mol) 9.76 ± 0.38 9.35 ± 0.39 10.02 ± 0.20 10.44 ± 0.35** 9.26 ± 0.45 11.74 ± 0.57**
Lipid-corrected total tocopherol (g/mol) 9.16 ± 0.37 8.78 ± 0.40 9.53 ± 0.22 9.83 ± 0.37** 8.55 ± 0.41 10.96 ± 0.54**
Lipid-corrected total tocotrienol (g/mol) 0.63 ± 0.07 0.57 ± 0.06 0.54 ± 0.06 0.62 ± 0.06 0.69 ± 0.08 0.78 ± 0.07**
Vitamin C (mg/L) 5.09 ± 0.30 4.23 ± 0.26 5.86 ± 0.30* 5.29 ± 0.29** 6.07 ± 0.31** 5.14 ± 0.37**
Values are expressed as mean ± SEM.
Symbols indicate significant difference from baseline (0 month).
*: p < 0.05, **: p < 0.01
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groups regardless of the treatment received. Further
analysis of age groups showed similar increases for all
groups to varying degrees of significance.
Antioxidant enzymes
A significant effect for duration was observed in SOD
activity with TRF treatment (F = 6.838, p = 0.006, effect
size = 0.229, power = 0.826) as well as in CAT and GPx
activity with placebo (F = 4.185, p = 0.002, effect size =
0.160, power = 0.707 and F = 5.271, p = 0.009, effect
size = 0.193, power = 0.809 respectively). SOD activity
decreased after 3 and 6 months of TRF treatment
(Table 5); these effects were seen in both younger and
older groups, although only the > 50 year-old group
reached statistical significance (Table 6). CAT activity
was decreased in the placebo group after 3 months; this
change was also only observed in the > 50 year-old
group. Similar effects were observed for GPx, where
only subjects in the > 50 year-old group showed
increased activity after 6 months regardless of treatment.
There was nearly no association between SOD activity
and age (Figure 1), whereas GPx activity slightly
declined with age (Figure 2), while CAT activity slightly
increased with age (Figure 3); however, none of these
correlations was significant. Supplementation with TRF
strengthened the relationship between SOD activity and
age as well as for CAT activity. GPx activity was
reversed in the older individuals in association with age.
Oxidative markers
Changes in protein carbonyl levels were statistically sig-
nificant with duration of treatment (F = 6.193, p =
0.008, effect size = 0.212, power = 0.810). Protein carbo-
nyl content was significantly decreased after 6 months
of TRF treatment (p = 0.002) as compared to baseline
Table 4 Plasma antioxidant vitamins according to age group
Age group
Antioxidant vitamins 35-49 years > 50 years
Placebo TRF Placebo TRF
Lipid-corrected total vitamin E (g/mol)
Baseline (0 month) 8.71 ± 0.37 8.57 ± 0.43 10.41 ± 0.50 9.89 ± 0.56
3 months 9.49 ± 0.24 9.59 ± 0.46 10.35 ± 0.25 11.03 ± 0.45*
6 months 9.04 ± 0.67 10.39 ± 0.53** 9.52 ± 0.61 12.89 ± 0.85**
Lipid-corrected total tocopherol (g/mol)
Baseline (0 month) 8.04 ± 0.33 7.89 ± 0.45 9.84 ± 0.47 9.39 ± 0.57
3 months 8.92 ± 0.35 8.86 ± 0.46 9.92 ± 0.29 10.49 ± 0.48*
6 months 8.20 ± 0.62 9.66 ± 0.52** 8.97 ± 0.52 12.06 ± 0.79**
Lipid-corrected total tocotrienol (g/mol)
Baseline (0 month) 0.69 ± 0.09 0.66 ± 0.08 0.58 ± 0.11 0.50 ± 0.07
3 months 0.61 ± 0.07 0.73 ± 0.11 0.46 ± 0.09 0.54 ± 0.07
6 months 0.80 ± 0.09 0.73 ± 0.09 0.55 ± 0.14 0.82 ± 0.11**
Vitamin C (mg/L)
Baseline (0 month) 4.61 ± 0.35 3.95 ± 0.19 5.57 ± 0.47 4.50 ± 0.48
3 months 5.26 ± 0.42 5.16 ± 0.43* 6.48 ± 0.36 5.42 ± 0.39*
6 months 5.66 ± 0.32** 4.98 ± 0.63 6.66 ± 0.56 5.26 ± 0.46**
Values are expressed as mean ± SEM.
Symbols indicate significant difference from baseline (0 month).
*: p < 0.05, **: p < 0.01
Table 5 Erythrocyte antioxidant enzymes activity in placebo and TRF groups
Duration
Antioxidant enzymes 0 month 3 months 6 months
Placebo TRF Placebo TRF Placebo TRF
Superoxide dismutase (U/mg Hb) 1.90 ± 0.09 2.29 ± 0.14 1.90 ± 0.16 1.83 ± 0.09** 1.91 ± 0.13 1.77 ± 0.09**
Catalase (U/mg Hb) 0.30 ± 0.01 0.28 ± 0.01 0.24 ± 0.01** 0.27 ± 0.01 0.27 ± 0.01 0.27 ± 0.01
Glutathione peroxidase (U/mg Hb) 0.82 ± 0.05 0.87 ± 0.04 0.87 ± 0.05 1.04 ± 0.08 1.04 ± 0.05** 1.09 ± 0.06*
Values are expressed as mean ± SEM.
Symbols indicate significant difference from baseline (0 month).
*: p < 0.05, **: p < 0.01
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Page 7 of 14(0 month) (Table 7). Further grouping by age (Table 8)
revealed a marked reduction (p < 0.001) in the > 50
year-old group after 6 months of treatment. Nonethe-
less, no significant effect for duration was obtained in
AGE and MDA levels despite both levels were reduced
in the older TRF-treated group after 3 months and
remained low thereafter; however, this tendency did not
reach significance.
The relationships between age and oxidative stress
marker levels are shown in Figures 4, 5 and 6. All mea-
sured biomarkers (protein carbonyl, AGE and MDA)
were weakly correlated with age. TRF treatment reversed
these relationships, particularly for MDA, which showed
a correlation coefficient of close to 0.4 (p < 0.05).
Discussion
Human ageing is affected by both genetic factors and
lifestyle-related factors such as diet. Dietary intervention
is feasible, as nutrients can affect the rate of ageing by
altering the type and quantity of proteins synthesized
[37] by modulating gene expression [38], thereby alter-
ing the oxidative status of individuals [39].
Our results indicate that daily supplementation for up
to 6 months with TRF raised plasma HDL cholesterol
Table 6 Erythrocyte antioxidant enzymes activity according to age group
Age group
Antioxidant enzymes 35-49 years > 50 years
Placebo TRF Placebo TRF
Superoxide dismutase (U/mg Hb)
Baseline (0 month) 1.85 ± 0.14 2.23 ± 0.22 1.89 ± 0.12 2.35 ± 0.20
3 months 1.95 ± 0.16 1.81 ± 0.15 1.85 ± 0.28 1.85 ± 0.12*
6 months 1.98 ± 0.24 1.74 ± 0.14 1.85 ± 0.10 1.79 ± 0.12*
Catalase (U/mg Hb)
Baseline (0 month) 0.29 ± 0.02 0.28 ± 0.02 0.32 ± 0.02 0.28 ± 0.01
3 months 0.25 ± 0.01 0.25 ± 0.02 0.23 ± 0.01** 0.29 ± 0.02
6 months 0.29 ± 0.02 0.23 ± 0.02 0.24 ± 0.02* 0.30 ± 0.02
Glutathione peroxidase (U/mg Hb)
Baseline (0 month) 0.74 ± 0.07 0.89 ± 0.06 0.90 ± 0.06 0.86 ± 0.06
3 months 0.87 ± 0.10 1.02 ± 0.15 0.88 ± 0.06 1.07 ± 0.08
6 months 0.88 ± 0.06 1.05 ± 0.13 1.19 ± 0.06* 1.12 ± 0.06*
Values are expressed as mean ± SEM.
Symbols indicate significant difference from baseline (0 month).
*: p < 0.05, **: p < 0.01
Figure 1 Correlation between superoxide dismutase activity
and age with TRF treatment for 6 months. TRF supplementation
strengthened the association after 6 months. 0 month: r = 0.04, p =
0.81; 3 months: r = 0.06, p = 0.73; 6 months: r = 0.26, p = 0.21.
Figure 2 Correlation between glutathione peroxidase activity
and age with TRF treatment for 6 months. TRF supplementation
reversed the relationship after 6 months. 0 month: r = -0.17, p =
0.40; 3 months: r = -0.16, p = 0.41; 6 months: r = 0.05, p = 0.82.
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Page 8 of 14levels as early as 3 months, thereby increasing the HDL-
cholesterol/total cholesterol ratio. This ratio reflects the
proportion of anti-atherogenic to atherogenic lipids and
has been suggested as a better predictor of cardiovascu-
lar disease risk than the individual lipoprotein values
[40]. TRF might thus help to reduce the risk of coronary
heart disease (CHD) in healthy older adults. In fact,
HDL cholesterol increases of the magnitude observed in
this study have been associated with a 22.5% reduced
risk of cardiovascular events [41]. Raising plasma HDL
cholesterol and thus the HDL-cholesterol/total choles-
terol is recommended by the American Diabetes Asso-
ciation (ADA) guidelines together with lowering plasma
triglycerides for high-risk individuals particularly older
adults as major mortality cases of CHD were 65 years
old or older [42].
Conflicting data have been reported regarding effects
of vitamin E supplementation which were mainly a-
tocopherol on HDL cholesterol. Increased HDL choles-
terol after a-tocopherol supplementation has been
reported by some investigators [43-45] and disputed by
others [46,47]. It should be noted that the supplement
used in this study was high in tocotrienols, which has
been reported to have different effect from a-tocopherol
[48]. Tocotrienol but not tocopherol increases HDL
cholesterol by inhibiting HMG-CoA reductase through
signalling, thereby regulating cholesterol biosynthesis
[49]. Tocotrienol may increase HDL in this study by
modulating signal transduction and gene expression;
specifically, and may normalize any aberrant gene
expression incurred by aging [50]. Increases in HDL
could be attained by increasing physical exercise [51,52]
but similar effects by supplementation of vitamins have
not been reported in human.
Compliance of the subjects was indicated by the
observed increase in plasma lipid-corrected total toco-
trienol and tocopherol concentration. Standardization of
plasma vitamin E levels to total cholesterol was neces-
sary to control for age-related changes in baseline cho-
lesterol levels as vitamin E is transported by the
lipoproteins. The finding that tocotrienol levels were
increased is of particular interest, as tocotrienol is now
reported to have functions distinct from a-tocopherol as
reviewed by Sen et al. [53]. The marked increase in
tocotrienol in the > 50 age group is interesting and sug-
gests an increased bioavailability and possibly the need
for tocotrienol with aging. The level of total tocotrienol
was slightly lower in the older adults as opposed to the
younger group. Supplementation of older subjects with
TRF restored plasma vitamin E availability to near the
levels of in the controls of the younger group. We spec-
ulate that a steady state plasma vitamin E concentration
was achieved after 6 months of supplementation, as
plasma concentrations were similar to those in the
younger group were seen at that time point. Some stu-
dies have reported the achievement of steady-state
plasma vitamin E levels after 10 to 15 days of supple-
mentation with either natural or synthetic forms of a-
tocopherol at much higher dosages [54-56]. Considering
the well-documented preferential absorption and trans-
portation of different vitamin E isomers in the body and
Figure 3 Correlation between catalase activity and age with
TRF treatment for 6 months. TRF supplementation strengthened
the association after 3 and 6 months. 0 month: r = 0.16, p = 0.41; 3
months: r = 0.36, p = 0.06; 6 months: r = 0.23, p = 0.26.
Table 7 Oxidative markers in placebo and TRF groups
Duration
Oxidative Markers 0 month 3 months 6 months
Placebo TRF Placebo TRF Placebo TRF
Protein carbonyl (nmol/mg) 0.52 ± 0.05 0.63 ± 0.04 0.51 ± 0.05 0.53 ± 0.04 0.56 ± 0.05 0.45 ± 0.04**
Advanced glycosylation end-product (units/ml) 2.37 ± 0.11 2.38 ± 0.19 2.00 ± 0.15 2.40 ± 0.18 1.93 ± 0.17 1.92 ± 0.14
Malondialdehyde (nmol/ml) 4.21 ± 0.19 4.10 ± 0.30 4.00 ± 0.24 3.90 ± 0.25 3.91 ± 0.23 4.14 ± 0.22
Values are expressed as mean ± SEM.
Symbols indicate significant difference from baseline (0 month).
**: p < 0.01
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Page 9 of 14by taking into account the tocotrienol-rich composition
i nt h eT R F ,s u c has l o wb u ts t e a d yi n c r e m e n ti s
reasonable.
The tocotrienols are found in a wide variety of foods
a n di th a sb e e ns u g g e s t e dr e c e n t l yt h a ta l l8i s o m e r so f
vitamin E may be necessary for optimum health [24].
This requirement maybe more crucial for the older indi-
viduals where digestion and absorption may not be as
efficient resulting in the potential benefits of supplemen-
tation. Differences noted in the plasma levels of toco-
trienols detected in various human studies are mainly
due to the different daily fat diet. Asians consume
higher levels of palm oil rich in tocotrienols. Therefore,
a comparatively higher absorption of tocotrienol and
thus better level found in circulation.
The elevated plasma vitamin C level detected in the
present study was most likely absorbed from the diet, as
the supplement is not a source of vitamin C. Indeed, we
found a positive correlation between vitamin C intake
and plasma vitamin C levels (r = 0.308, p = 0.048). This
is in accordance with findings by Padayatty et al. [57]
who had reported that small changes in oral intake of
Table 8 Oxidative markers according to age group
Age group
Oxidative markers 35-49 years > 50 years
Placebo TRF Placebo TRF
Protein carbonyl (nmol/mg)
Baseline (0 month) 0.54 ± 0.08 0.58 ± 0.08 0.50 ± 0.06 0.63 ± 0.03
3 months 0.56 ± 0.13 0.54 ± 0.05 0.48 ± 0.05 0.52 ± 0.06
6 months 0.60 ± 0.08 0.51 ± 0.06 0.47 ± 0.04 0.40 ± 0.03**
Advanced glycosylation end-product (units/ml)
Baseline (0 month) 2.39 ± 0.15 2.10 ± 0.22 2.34 ± 0.22 2.73 ± 0.26
3 months 2.01 ± 0.18 2.38 ± 0.21 2.30 ± 0.26 2.24 ± 0.35
6 months 2.12 ± 0.22 2.02 ± 0.17 1.98 ± 0.25 1.71 ± 0.24*
Malondialdehyde (nmol/ml)
Baseline (0 month) 4.25 ± 0.30 3.45 ± 0.37 4.18 ± 0.23 4.71 ± 0.41
3 months 4.82 ± 0.34 3.95 ± 0.39 3.22 ± 0.22 3.86 ± 0.34
6 months 3.95 ± 0.31 4.48 ± 0.27 3.87 ± 0.36 3.87 ± 0.32
Values are expressed as mean ± SEM.
Symbols indicate significant difference from baseline (0 month).
*: p < 0.05, **: p < 0.001
Figure 4 Correlation between plasma protein carbonyl levels
and age with TRF treatment for 6 months. TRF supplementation
weakened the association after 3 and 6 months. 0 month: r = 0.21,
p = 0.31; 3 months: r = 0.004, p = 0.98; 6 months: r = -0.15, p =
0.47.
Figure 5 Correlation between serum advanced glycosylation
end-products and age with TRF treatment for 6 months. TRF
supplementation reversed the association after 3 and 6 months. 0
month: r = 0.18, p = 0.21; 3 months: r = -0.13, p = 0.37; 6 months: r
= -0.12, p = 0.47.
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concentration. The increase in plasma vitamin C might
also result from a complementary effect by vitamin E in
an interlinking antioxidant network. The involvement of
vitamin C in regenerating vitamin E directly from its
tocotrienoxyl or tocopheroxyl radical back to tocotrienol
and tocopherol respectively has been well documented
[58]. Increased levels of vitamin E might reflect
increased reactions with reactive free radicals, additional
formation of tocotrienoxyl or tocopheroxyl radical, and
a further increased need for vitamin C.
The variation observed in enzyme activity might have
been due to the different roles of the analysed antioxi-
dant enzymes. The functional roles of these enzymes are
well established, with SOD acting upstream by dismutat-
ing reactive superoxide anion radicals into more stable
hydrogen peroxide (H2O2) whereas catalase and GPx
function downstream by converting H2O2 into water
and oxygen in apparently parallel pathways. Changes in
antioxidant enzymes activity observed were clearly in
favour of the > 50 years old group. Reduction in SOD
activity with TRF supplementation after 3 and 6 months
in the older group possibly due to lesser formation of
radicals as a result of radical scavenging effect by toco-
trienol and tocopherol. On the other hand, increase in
GPx activity in both placebo and TRF group after 6
months possibly due to higher need for H2O2 removal.
Increased level of tocotrienol and tocopherol attained by
TRF supplementation might reflect more radical scaven-
ging activity, followed by increased H2O2 formation and
therefore increased requirement for its removal. As for
the placebo group, increased intake of dietary vitamin C
might results in a similar increase in radical scavenging
activity and the subsequent reactions involving forma-
tion and detoxification of H2O2. Given a decline in the
catalase activity in the placebo group, the action of
removing H2O2 was predominantly done by GPx. In the
current study, the enzymes activity measured was evi-
dently influenced by TRF supplementation as shown by
the shifted correlation patterns with age.
Long term supplementation of TRF for 6 months
caused the increase in plasma vitamin E availability
(both tocopherol and tocotrienol) observed in the cur-
rent study, accompanied by changes in the oxidative
stress biomarkers measured. Protein carbonyls have
been described as oxidized amino acids resulting from
direct oxidation of protein by reactive oxygen species
[59]. Proteins are also modified indirectly by glycation
or glycoxidation of amino groups with the eventual for-
mation of the advanced glycosylation end products
(AGEs) [60]. Consistent with the fall in plasma concen-
trations of carbonylated protein with TRF supplementa-
tion, a sharp decrease in serum AGE was observed.
When the effect of age was factored out of the statistical
model, it was found that the interaction between supple-
mentation and duration was significant for the older
individuals, indicating a favourable gain in the older
group. Figures 4, 5 and 6 give individual presentations
of the changes in these oxidative markers with age.
Ascending trends of protein damage and lipid peroxida-
tion accumulation during ageing as shown by the corre-
lative data were reduced, even reversed by TRF
supplementation. These findings confirm that nutritional
intervention can exert cumulative effects on oxidative
stress in healthy individuals in the long term [27]. The
unique combination of vitamin E isomers used in the
study might have acted synergistically to provide the
beneficial effect.
The reduced levels of oxidative markers were mainly
observed in the older group, for whom the lower cut-off
point was 50 years of age. This is of interest as previous
studies typically evaluated older subjects, mostly 60
years old and over. It is also noteworthy that in the pre-
sent study the treatment was administered to healthy
individuals for a lengthy period of 6 months and studies
involving supplementation of this duration are fairly
limited. This may then results in the observed changes
in oxidative status as measured by protein carbonyl and
AGE. Although some of the younger subjects in the
study also showed increased levels of antioxidant vita-
mins, the magnitude of changes was less evident as
compared to the older individuals. The absence or lack
of response by the younger age group might reflect a
well-maintained antioxidant level, more effective mainte-
nance of oxidative balance, and better defence against
spontaneous oxidative injury. It is thus possible that
Figure 6 Correlation between plasma malondialdehyde levels
and age with TRF treatment for 6 months. TRF supplementation
reversed the association after 3 and 6 months. 0 month: r = 0.17, p
= 0.25; 3 months: r = -0.19, p = 0.22; 6 months: r = -0.37, p = 0.02.
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Page 11 of 14TRF supplementation did not provide any further
improvement. Although baseline antioxidant levels in
the > 50 year-old group were similar to those in the <
50 year-old group, baseline oxidative marker levels were
higher in the older group, suggesting a higher level of
oxidative damage. However, the amount of damaged
lipids and proteins in this group was reduced by supple-
mentation, probably due to the increased requirement
for antioxidants in older individuals. It is possible that
an antioxidant threshold for optimum performance
exists and that this threshold (and therefore the require-
ment for antioxidants) could increase with ageing, thus
allowing supplementation to generate an effect in the
present study. A long-term prospective study will be
required to test this hypothesis, particularly at the mole-
cular level.
Compelling evidence suggests a new level of action for
vitamin E under the non-antioxidative control in protec-
tion against disease [50]. Therefore, TRF might not only
act directly or solely as an antioxidant, but it may actually
also act through signalling pathways and specific signal-
regulated protein reaction as suggested by Sen et al.
[14,61]. Tocotrienol was shown to provide complete neu-
roprotection via antioxidant-independent mechanism with
t h ep r o t e c t i v ep r o p e r t yr eported not only limited in
response to non-oxidative challenges but also to oxidative
insults [14,15]. Further studies of the effects of tocotrienols
in a cell model are currently underway in our laboratory.
Conclusion
Our data revealed an age-related increase in oxidative
damage. We established a role of nutritional supplemen-
tation in oxidative damage and antioxidant levels in
older individuals. To our best knowledge, tocotrienol-
rich vitamin E supplementation has not yet been studied
in relation to oxidative stress in healthy older indivi-
duals. Consistent with increased concentrations of
plasma antioxidants (vitamins E and C), we observed
significant decreases in protein carbonyl and AGE levels,
as well as improvement of plasma cholesterol levels.
The protective effects of TRF supplementation observed
in this study might represent a restoration of redox bal-
ance, particularly in the > 50-year old group. Increased
tocotrienol level might be an important mechanism by
which TRF supplementation confers its protective bene-
fits via protection against oxidative stress, involvement
in oxidized protein repair, besides contributing to the
regulation of redox homeostasis through signalling.
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